FDA-approved peptides: which compounds have a Drugs@FDA approval

Which peptides are FDA approved?

Of the 28 compounds PeptideTech has checked in Drugs@FDA, 11 peptides share an active ingredient with an FDA-approved medicine: Liraglutide (Victoza and Saxenda), Melanotan-1 (Scenesse), Oxytocin (Pitocin), Bremelanotide (Vyleesi), Semaglutide (Ozempic, Rybelsus and Wegovy), Elamipretide (Forzinity), Tesamorelin (Egrifta), Tirzepatide (Mounjaro and Zepbound) and Triptorelin (Trelstar and Triptodur) are marketed, and Gonadorelin (Factrel and Lutrepulse Kit) and Sermorelin (Geref) were approved but are now listed as discontinued. Drugs@FDA lists no approved application for 15 other checked compounds, including BPC-157, Retatrutide, Ipamorelin and Ibutamoren. A research-labelled listing is never the approved medicine (checked October 7, 2026).

Source: Drugs@FDA (U.S. Food and Drug Administration)

Are research peptides FDA approved?

No. A product sold as a research-use-only peptide is not an FDA-approved drug, even when its active ingredient is also the active ingredient of an approved medicine. Approval covers a specific manufacturer, formulation, labelling and indication; it does not transfer to a research-labelled vial.

Is BPC-157 FDA approved?

No. Drugs@FDA lists no NDA, BLA or ANDA with BPC-157 as an active ingredient (names searched: BPC-157, BPC 157, BEPECIN; checked October 7, 2026). ClinicalTrials.gov lists 3 registered studies naming it as an intervention, which describe protocols rather than approvals.

Source: Drugs@FDA (U.S. Food and Drug Administration)

Is Retatrutide FDA approved?

No. Drugs@FDA lists no NDA, BLA or ANDA with retatrutide as an active ingredient (names searched: RETATRUTIDE, LY3437943; checked October 7, 2026). ClinicalTrials.gov lists 34 registered studies naming it as an intervention, which describe protocols rather than approvals.

Source: Drugs@FDA (U.S. Food and Drug Administration)

Is Ipamorelin FDA approved?

No. Drugs@FDA lists no NDA, BLA or ANDA with ipamorelin as an active ingredient (names searched: IPAMORELIN, IPAMORELIN ACETATE; checked October 7, 2026). ClinicalTrials.gov lists 2 registered studies naming it as an intervention, which describe protocols rather than approvals.

Source: Drugs@FDA (U.S. Food and Drug Administration)